134 related articles for article (PubMed ID: 9832968)
1. Further pharmacological validation of the BALB/c neophobia in the free exploratory paradigm as an animal model of trait anxiety.
Belzung C; Berton F
Behav Pharmacol; 1997 Nov; 8(6-7):541-8. PubMed ID: 9832968
[TBL] [Abstract][Full Text] [Related]
2. PD135158, a CCK-B antagonist, reduces "state," but not "trait" anxiety in mice.
Belzung C; Pineau N; Beuzen A; Misslin R
Pharmacol Biochem Behav; 1994 Oct; 49(2):433-6. PubMed ID: 7824561
[TBL] [Abstract][Full Text] [Related]
3. Antagonistic effects of S 22153, a new mt1 and MT2 receptor ligand, on the neophobia-reducing properties of melatonin in BALB/c mice.
Kopp C; Vogel E; Rettori MC; Delagrange P; Renard P; Lesieur D; Misslin R
Pharmacol Biochem Behav; 1999 Sep; 64(1):131-6. PubMed ID: 10495007
[TBL] [Abstract][Full Text] [Related]
4. Effects of melatonin on neophobic responses in different strains of mice.
Kopp C; Vogel E; Rettori MC; Delagrange P; Guardiola-Lemaître B; Misslin R
Pharmacol Biochem Behav; 1999 Aug; 63(4):521-6. PubMed ID: 10462179
[TBL] [Abstract][Full Text] [Related]
5. Further evidence for differences between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands in murine models of "state" and "trait" anxiety.
Griebel G; Sanger DJ; Perrault G
Neuropharmacology; 1996; 35(8):1081-91. PubMed ID: 9121611
[TBL] [Abstract][Full Text] [Related]
6. The free-exploratory paradigm: an effective method for measuring neophobic behaviour in mice and testing potential neophobia-reducing drugs.
Griebel G; Belzung C; Misslin R; Vogel E
Behav Pharmacol; 1993 Dec; 4(6):637-644. PubMed ID: 11224232
[TBL] [Abstract][Full Text] [Related]
7. An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice.
Belzung C; Le Guisquet AM; Barreau S; Calatayud F
Behav Pharmacol; 2001 Jun; 12(3):151-62. PubMed ID: 11485052
[TBL] [Abstract][Full Text] [Related]
8. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines.
Crawley JN
Pharmacol Biochem Behav; 1981 Nov; 15(5):695-9. PubMed ID: 6118883
[TBL] [Abstract][Full Text] [Related]
9. Absence of intrinsic antagonist actions of benzodiazepine antagonists on an exploratory model of anxiety in the mouse.
Crawley JN; Skolnick P; Paul SM
Neuropharmacology; 1984 May; 23(5):531-7. PubMed ID: 6146107
[TBL] [Abstract][Full Text] [Related]
10. Effects of anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice.
Kilfoil T; Michel A; Montgomery D; Whiting RL
Neuropharmacology; 1989 Sep; 28(9):901-5. PubMed ID: 2572995
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological validation of the free-exploratory paradigm in male Wistar rats: A proposed test of trait anxiety.
Almeida-Souza TH; Goes TC; Teixeira-Silva F
Pharmacol Biochem Behav; 2015 Aug; 135():114-20. PubMed ID: 26028610
[TBL] [Abstract][Full Text] [Related]
12. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.
Chopin P; Briley M
Psychopharmacology (Berl); 1993; 110(4):409-14. PubMed ID: 7870910
[TBL] [Abstract][Full Text] [Related]
13. Naloxone blocks anxiolytic-like effects of benzodiazepines in Swiss but not in Balb/c mice.
Belzung C; Agmo A
Psychopharmacology (Berl); 1997 Jul; 132(2):195-201. PubMed ID: 9266617
[TBL] [Abstract][Full Text] [Related]
14. Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze.
Dunn RW; Corbett R; Fielding S
Eur J Pharmacol; 1989 Oct; 169(1):1-10. PubMed ID: 2574684
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological modulation of anxiety-related behaviors in the murine Suok test.
Kalueff AV; Keisala T; Minasyan A; Tuohimaa P
Brain Res Bull; 2007 Sep; 74(1-3):45-50. PubMed ID: 17683788
[TBL] [Abstract][Full Text] [Related]
16. The benzodiazepine diazepam demonstrates the usefulness of Syrian hamsters as a model for anxiety testing: evaluation of other classes of anxiolytics in comparison to diazepam.
Gannon RL; Lungwitz E; Batista N; Hester I; Huntley C; Peacock A; Delagrange P; Millan MJ
Behav Brain Res; 2011 Mar; 218(1):8-14. PubMed ID: 21094664
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the predictive validity of the mirror chamber and elevated plus maze tests in mice.
Paterson NE; Iwunze M; Davis SF; Malekiani SA; Hanania T
J Neurosci Methods; 2010 Apr; 188(1):62-70. PubMed ID: 20149823
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.
Stemmelin J; Cohen C; Terranova JP; Lopez-Grancha M; Pichat P; Bergis O; Decobert M; Santucci V; Françon D; Alonso R; Stahl SM; Keane P; Avenet P; Scatton B; le Fur G; Griebel G
Neuropsychopharmacology; 2008 Feb; 33(3):574-87. PubMed ID: 17460614
[TBL] [Abstract][Full Text] [Related]
19. Prototypical anxiolytics do not reduce anxiety-like behavior in the open field in C57BL/6J mice.
Thompson T; Grabowski-Boase L; Tarantino LM
Pharmacol Biochem Behav; 2015 Jun; 133():7-17. PubMed ID: 25812472
[TBL] [Abstract][Full Text] [Related]
20. The alpha-2 antagonists idazoxan and rauwolscine but not yohimbine or piperoxan are anxiolytic in the Vogel lick-shock conflict paradigm following intravenous administration.
La Marca S; Dunn RW
Life Sci; 1994; 54(10):PL179-84. PubMed ID: 7906377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
